Skip to main content
. 2019 Oct 14;11(10):1558. doi: 10.3390/cancers11101558

Figure 2.

Figure 2

The most frequently used systemic anticancer therapy (SACT) regimens in the metastatic setting in (a) first line, (b) second line, (c) third line, and (d) fourth line setting. Epidermal Growth Factor Receptor (EGFR) Monoclonal antibody (MoAb) therapy (cetuximab 500 mg/m2 2-weekly or panitumumab 6 mg/kg 2-weekly) was only offered in patients with known KRAS wild type tumors. FOLFIRI (14 day cycle: 5FU bolus 400 mg/m2 and 5FU 2400 mg/m2 infusion over 48 h, folinic acid 350 mg and irinotecan 180 mg/m2 day 1), CAPIRI (21 day cycle: capecitabine 1700 mg/m2 per day in two divided doses for 14 days followed by 7 day rest and irinotecan 200 mg/m2 on day 1), FOLFOX (14 day cycle: 5FU bolus 400 mg/m2,5FU 2400 mg/m2 infusion over 48 h folinic acid 350 mg and oxaliplatin 85 mg/m2 on day 1), CAPOX (21 day cycle: capecitabine 1700 mg/m2 per day in two divided doses for 14 days followed by 7 day rest and oxaliplatin 130 mg/m2 on day 1). Bevacizumab in all 3-weekly regimens at 7.5 mg/kg, 2 weekly regimens at 5 mg/kg. Aflibercept at 4 mg/kg 2 weekly. Regorafenib 4 weekly cycles at 160 mg once a day (OD) for 21 days followed by 7-day rest.